Barron’s Tepid Review of Amylin Pharmaceuticals (AMLN, PFE, NKTR, SNY, NVO)

In Barron’s this past weekend, Bill Alpert discussed the prospects for Amylin Pharmaceuticals (ticker: AMLN). His conclusion: Amylin’s drug, Byetta, “…could emerge as a star in the war against diabetes despite competition and…a possible link to a rare cancer. But all the good news already appears to be in the stock price.